View Future GrowthCORESTEMCHEMON 過去の業績過去 基準チェック /06CORESTEMCHEMONの収益は年間平均-15.1%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間15.2% 8.7%割合で 減少しています。主要情報-15.06%収益成長率0.044%EPS成長率Biotechs 業界の成長11.70%収益成長率-8.65%株主資本利益率-66.44%ネット・マージン-173.97%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • Nov 19Third quarter 2023 earnings released: ₩219 loss per share (vs ₩362 loss in 3Q 2022)Third quarter 2023 results: ₩219 loss per share (improved from ₩362 loss in 3Q 2022). Revenue: ₩6.47b (down 35% from 3Q 2022). Net loss: ₩4.68b (loss narrowed 19% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 26Second quarter 2023 earnings released: ₩115 loss per share (vs ₩237 profit in 2Q 2022)Second quarter 2023 results: ₩115 loss per share (down from ₩237 profit in 2Q 2022). Revenue: ₩9.85b (down 25% from 2Q 2022). Net loss: ₩2.45b (down 165% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.すべての更新を表示Recent updatesNew Risk • Jun 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩140.8b (US$93.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (82% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩140.8b market cap, or US$93.4m).New Risk • Apr 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩15b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩15b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 9.0% per year over the past 5 years. Shareholders have been substantially diluted in the past year (82% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩105.1b market cap, or US$69.7m).お知らせ • Feb 24CORESTEMCHEMON Inc., Annual General Meeting, Mar 27, 2026CORESTEMCHEMON Inc., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 240, nampyeong-ro, yangji-eup, cheoin-gu, gyeonggi-do, yongin South Korea分析記事 • Jan 23CORESTEMCHEMON Inc. (KOSDAQ:166480) Shares Fly 46% But Investors Aren't Buying For GrowthCORESTEMCHEMON Inc. ( KOSDAQ:166480 ) shareholders have had their patience rewarded with a 46% share price jump in the...お知らせ • Dec 18Corestemchemon Advances Toward Als Stem Cell Commercialization with Regulatory Progress in Korea and Nsf-Backed U.S. ExpansionCorestemChemon is entering a critical late-stage phase in the commercialization of its ALS stem cell therapy, Neuronata-R. The company attributes this momentum to advanced domestic regulatory review in Korea, entry into an NSF-supported regenerative medicine ecosystem in the United States, secured commercialization capital, and a sizable open-market share purchase by the CEO. In Korea, Neuronata-R is undergoing a product license modification review by the Ministry of Food and Drug Safety (MFDS). Following mixed efficacy results in the overall patient population in the Phase 3 ALSUMMIT trial, CorestemChemon refined its regulatory strategy to focus on a clinically defined " slow progressor" subgroup. Post-hoc analyses in this subgroup showed clinically meaningful and internally consistent signals, including maintenance of ALS Functional Rating Scale-Revised (ALSFRS-R) scores, stabilization of slow vital capacity (SVC), and favorable trends in neurofilament light chain (NfL) biomarkers. The company believes these findings have supported a more structured and focused regulatory dialogue with the MFDS. The company expects this precision-targeted approach to further clarify the domestic regulatory pathway, while preserving the option for initial commercialization upon potential approval. A favorable MFDS decision would enable domestic market entry and generation of real-world evidence (RWE), which could support future global regulatory strategies. The company expects a final regulatory decision in Korea before the first quarter of 2026. CorestemChemon has been selected to join the Piedmont Triad Regenerative Medicine Innovation Engine, a U.S. regional innovation cluster supported by the National Science Foundation (NSF). The company stated that it is the first Korean biotechnology firm to be included in an NSF-backed regenerative medicine ecosystem. The selection was initiated by the Wake Forest Institute for Regenerative Medicine (WFIRM), which cited the scientific robustness of Neuronata-R's Phase 3 clinical dataset and the consistency observed in long-term real-world follow-up data. Participants in the NSF Engine is expected to provide access to translational research capabilities, manufacturing resources, and a broader regulatory network. To align more closely with this ecosystem, CorestemChemon plans to relocate its U.S. subsidiary to North Carolina. The company intends to leverage the cluster as a platform for regulatory engagement with the U.S. Food and Drug Administration (FDA), targeting submission of a Biologics License Application (BLA) in the third quarter of 2026. Commercialization Funding and Financial Position: To support commercialization readiness following potential domestic approval, CorestemChemon recently completed a rights offering, raising KRW 26.1 billion in operating capital (approximately USD 17.8 million, based on recent exchange rates). The proceeds are allocated to upgrading production facilities, establishing commercial-scale manufacturing systems, and preparing for both domestic and global regulatory processes. The company expects the capital raise to strengthen its financial position and reduce execution risk associated with manufacturing scale-up and regulatory preparation, while addressing near-term funding concerns. In a move widely interpreted as reinforcing market confidence, CEO Yang Gil-ahn recently executed a large-scale open-market share purchase. Over a two-week period, he acquired more than one million shares, representing an investment of approximately KRW 1.7 billion (approximately USD 1.2 million, based on recent exchange rate). The purchase coincided with the submission of supplementary regulatory materials to the MFDS and is viewed as a signal of management's conviction at a key regulatory inflection point. Following the transaction, the combined ownership stake of the controlling shareholder group increased to 10.32%, further strengthening alignment between management and shareholders.分析記事 • Dec 03Investors Don't See Light At End Of CORESTEMCHEMON Inc.'s (KOSDAQ:166480) TunnelYou may think that with a price-to-sales (or "P/S") ratio of 3.4x CORESTEMCHEMON Inc. ( KOSDAQ:166480 ) is definitely a...New Risk • Nov 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 82% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (82% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩48.3b market cap, or US$33.0m).お知らせ • Nov 05CORESTEMCHEMON Inc. has completed a Follow-on Equity Offering in the amount of KRW 26.14 billion.CORESTEMCHEMON Inc. has completed a Follow-on Equity Offering in the amount of KRW 26.14 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: KRW 1307 Discount Per Security: KRW 23.526 Transaction Features: Rights Offeringお知らせ • Sep 18Neuronata- Phase 3 Results Confirm Subgroup Benefit at PACTALS 2025, Strengthening Biomarker-Driven PathwayCorestemChemon Inc. announced that it has presented key findings from the Phase 3 ALSummit trial of Neuronata-R® (lenzumestrocel), an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS), at the PACTALS 2025 congress in Melbourne, Australia. The first session, chaired by Professor Seung-Hyun Kim of Hanyang University Hospital — a global leader in stem cell-based ALS research — brought together a panel of seven distinguished ALS experts from six countries. As part of the panel, Dr. Ryung-A Lee (Head of R&D Innovation, CorestemChemon) introduced the company and shared a brief overview of the Phase 3 trial results. In the second session, the full Phase 3 clinical trial (ALSUMMIT trial) results were formally presented by Professor Ki-Uk Oh (Department of Neurology, Advanced Regenerative Medicine Center, Hanyang University Hospital, and principal investigator of the ALSUMMIT trial). Subgroup Analysis Demonstrates Statistically Significant Benefit: While the overall trial did not meet its primary and secondary endpoints, Neuronata-R® showed meaningful efficacy in patients with slower disease progression. At 12 months, participants in this subgroup receiving Neuronata-R achieved: ALSFRS-R (functional rating scale): 31.2 vs. 26.4 in placebo (p=0.001), CAFS (Combined Assessment of Function and Survival): 20.95 and 24.78 vs. 17.92 in placebo (p=0.024; p=0.041), SVC (slow vital capacity, respiratory function): 62.2% vs. 50.6% in placebo (p=0.017, Study Group 2). These findings confirm Neuronata-R's potential to preserve function and respiratory capacity in ALS — outcomes directly linked to quality of life and survival. Biomarker Data Underscore Neuroprotective Effect: Biomarker analysis revealed sustained reductions in neurofilament light chain (NfL) and MCP-1, indicating a strong link between neuroprotection and clinical outcomes. This strengthens the case for biomarker-guided patient stratification and a precision-medicine strategy in ALS drug development, reflecting the evolving global regulatory landscape. Regulatory Pathway Toward Accelerated Approval: CorestemChemon stated that the PACTALS 2025 results mark an important step for regulatory discussions. The company plans to request a Type-C meeting with the U.S. Food and Drug Administration (FDA) in Fourth Quarter 2025 to discuss the dataset and biomarker-driven subgroup efficacy. Based on this discussion, CorestemChemon plans to submit a Biologics License Application (BLA) within 2026, aiming to pursue an accelerated approval pathway aligned with precedents in ALS, including FDA's decision on Tofersen.お知らせ • Aug 20CORESTEMCHEMON Inc. has filed a Follow-on Equity Offering in the amount of KRW 37.8 billion.CORESTEMCHEMON Inc. has filed a Follow-on Equity Offering in the amount of KRW 37.8 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: KRW 1890 Discount Per Security: KRW 34.02 Transaction Features: Rights Offering分析記事 • Aug 19Why Investors Shouldn't Be Surprised By CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 40% Share Price PlungeThe CORESTEMCHEMON Inc. ( KOSDAQ:166480 ) share price has fared very poorly over the last month, falling by a...New Risk • Aug 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩42b free cash flow). Earnings have declined by 18% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩50.3b market cap, or US$36.2m).お知らせ • May 29Corestemchemon Announces Neuronata-R®? Stem Cell Therapy Shows Promise in Als Phase 3 Subgroup Analysis, Moves Toward Fda Accelerated ApprovalCorestemChemon announced Neuronata-R®?, an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS), has demonstrated meaningful efficacy signals in a subgroup of participants with slow disease progression in its recently completed Phase 3 trial. The therapy also showed consistent reductions in neurofilament light chain (NfL) levels -- a biomarker that served as the basis for FDA accelerated approval in ALS, including the recent decision on Tofersen -- supporting its potential to pursue a similar regulatory pathway. Developed by South Korean biotech company CorestemChemon, Neuronata-R®? utilizes MSCs derived from a participant's own bone marrow to modulate inflammation, protect motor neurons, and alter the neurodegenerative microenvironment through paracrine signaling. ALS, a rare and fatal disease with no cure, remains one of the most urgent areas of unmet medical need. Neuronata-R®®? aims to address the disease's complexology by leveraging the therapeutic potential of autologous MSCs. The final Clinical Study Report (CSR) confirmed that Neuronata-R®.分析記事 • Apr 14CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Price Is Right But Growth Is LackingYou may think that with a price-to-sales (or "P/S") ratio of 3x CORESTEMCHEMON Inc. ( KOSDAQ:166480 ) is definitely a...お知らせ • Feb 22CORESTEMCHEMON Inc., Annual General Meeting, Mar 28, 2025CORESTEMCHEMON Inc., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 240, nampyeong-ro, cheoin-gu, gyeonggi-do, yongin South Korea分析記事 • Feb 20Is CORESTEMCHEMON (KOSDAQ:166480) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Dec 20New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩123.5b (US$85.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩41b free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩123.5b market cap, or US$85.3m).New Risk • Dec 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩41b free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (14% increase in shares outstanding).分析記事 • Dec 09CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Popularity With Investors Under Threat As Stock Sinks 25%CORESTEMCHEMON Inc. ( KOSDAQ:166480 ) shares have had a horrible month, losing 25% after a relatively good period...分析記事 • Nov 01Is CORESTEMCHEMON (KOSDAQ:166480) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Sep 24CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 27% Price Boost Is Out Of Tune With RevenuesCORESTEMCHEMON Inc. ( KOSDAQ:166480 ) shares have had a really impressive month, gaining 27% after a shaky period...New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Shareholders have been diluted in the past year (2.6% increase in shares outstanding).分析記事 • Aug 03Would CORESTEMCHEMON (KOSDAQ:166480) Be Better Off With Less Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Jun 08What CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 26% Share Price Gain Is Not Telling YouCORESTEMCHEMON Inc. ( KOSDAQ:166480 ) shares have continued their recent momentum with a 26% gain in the last month...New Risk • May 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩26b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩26b free cash flow). Earnings have declined by 12% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).New Risk • Apr 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.1% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change).お知らせ • Mar 27CORESTEMCHEMON Inc. announced that it has received KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd.On March 26, 2024, CORESTEMCHEMON Inc., closed the transaction.分析記事 • Mar 05CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Shares Bounce 25% But Its Business Still Trails The IndustryCORESTEMCHEMON Inc. ( KOSDAQ:166480 ) shares have continued their recent momentum with a 25% gain in the last month...Reported Earnings • Nov 19Third quarter 2023 earnings released: ₩219 loss per share (vs ₩362 loss in 3Q 2022)Third quarter 2023 results: ₩219 loss per share (improved from ₩362 loss in 3Q 2022). Revenue: ₩6.47b (down 35% from 3Q 2022). Net loss: ₩4.68b (loss narrowed 19% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 26Second quarter 2023 earnings released: ₩115 loss per share (vs ₩237 profit in 2Q 2022)Second quarter 2023 results: ₩115 loss per share (down from ₩237 profit in 2Q 2022). Revenue: ₩9.85b (down 25% from 2Q 2022). Net loss: ₩2.45b (down 165% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.お知らせ • Jan 27CORESTEMCHEMON Inc. announced that it has received KRW 32.31145 billion in funding from a group of investorsOn January 26, 2023, CORESTEMCHEMON Inc. closed the transaction.お知らせ • Jan 18CORESTEMCHEMON Inc. announced that it expects to receive KRW 21.5 billion in funding from a group of investorsCORESTEMCHEMON Inc. announced a private placement of series 2 unregistered coupon unguaranteed private convertible bonds for gross proceeds of KRW 21,500,000,000 on January 17, 2023. The transaction will include participation from Kiwoom Securities Co., Ltd., Investment Arm, JB Woori Capital Co., Ltd, returning investors, Hanyang Securities Co. Ltd., Asset Management Arm, Samsung Securities Co. Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm and KB Securities Co., Ltd., Investment Arm. The zero coupon bonds will have a yield to maturity rate of 1% maturing on January 19, 2027. The series 2 bonds will be fully convertible into 2,423,900 common shares at an issue conversion price of KRW 8,870 per share between the period starting from February 19, 2023 and ending on December 19, 2026. The bonds have a lock-up period of one year from the date of issuance. The expected date of payment is January 19, 2023. The transaction has been approved by board of directors of the company.Valuation Update With 7 Day Price Move • Dec 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩8,380, the stock trades at a trailing P/E ratio of 34.9x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Negligible returns to shareholders over past three years.Valuation Update With 7 Day Price Move • Oct 11Investor sentiment improved over the past weekAfter last week's 26% share price gain to ₩11,650, the stock trades at a trailing P/E ratio of 23.6x. Average trailing P/E is 20x in the Biotechs industry in South Korea. Total returns to shareholders of 25% over the past three years.分析記事 • Apr 12Does CORESTEM (KOSDAQ:166480) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Feb 20New 90-day low: ₩19,150The company is down 8.0% from its price of ₩20,900 on 20 November 2020. The South Korean market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period.分析記事 • Feb 16If You Had Bought CORESTEM (KOSDAQ:166480) Shares A Year Ago You'd Have Earned 59% ReturnsCORESTEM Inc. ( KOSDAQ:166480 ) shareholders have seen the share price descend 18% over the month. But looking back...分析記事 • Dec 25Corestem (KOSDAQ:166480) Has Debt But No Earnings; Should You Worry?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Nov 16New 90-day low: ₩20,500The company is down 1.0% from its price of ₩20,650 on 18 August 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 3.0% over the same period.収支内訳CORESTEMCHEMON の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSDAQ:A166480 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Mar 2618,387-31,98811,6776,75031 Dec 2520,159-26,8339,3717,18730 Sep 2520,130-12,9239,73211,67830 Jun 2524,834-10,4288,81412,23831 Mar 2526,486-16,8867,59711,97631 Dec 2428,762-26,2527,58612,68230 Sep 2428,884-37,94510,0389,95330 Jun 2427,050-37,94210,26711,95631 Mar 2429,758-26,0777,55712,35131 Dec 2333,657-17,6729,55112,76330 Sep 2340,962-10,9919,64112,82330 Jun 2344,406-12,0658,83711,98431 Mar 2347,685-5,84010,29611,29731 Dec 2245,878-2,2579,32111,38530 Sep 2241,6334,485-2,11620,67430 Jun 2239,4927,47630017,52731 Mar 2234,068-14,5235,54313,39731 Dec 2130,240-6,9995,66712,13130 Sep 2130,054-30,83010,8745,88330 Jun 2128,593-30,9368,7095,88331 Mar 2126,694-13,7825,5726,51431 Dec 2026,358-23,1875,3625,88330 Sep 2025,381-8,2449,8281,59430 Jun 2024,552-6,3998,4462,28631 Mar 2024,783-5,6375,5634,37631 Dec 1924,284-5,1685,4583,85030 Sep 1923,741-3,6234,6843,39230 Jun 1924,598-2,8924,7533,32831 Mar 1921,926-3,8574,8373,10631 Dec 1822,317-3,3974,8652,93330 Sep 1818,889-3,5785,4113,65430 Jun 1817,553-3,8915,0883,56531 Mar 1819,178-3,2205,0283,44831 Dec 1718,094-4,0074,9303,16030 Sep 1719,883-3,2534,0162,79130 Jun 1720,077-2,0224,2982,25331 Mar 1719,541-1,7954,6081,86431 Dec 1617,953-1,6644,9661,48930 Sep 1618,510-8014,62766830 Jun 1618,661-1,3324,79066831 Mar 1618,733-7254,30366831 Dec 1518,571-5123,60966830 Sep 1516,785-2,9903,75497830 Jun 1514,636-5,5623,545978質の高い収益: A166480は現在利益が出ていません。利益率の向上: A166480は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A166480は利益が出ておらず、過去 5 年間で損失は年間15.1%の割合で増加しています。成長の加速: A166480の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: A166480は利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 22.6% ) と比較することは困難です。株主資本利益率高いROE: A166480は現在利益が出ていないため、自己資本利益率 ( -66.44% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/11 18:32終値2026/06/11 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CORESTEMCHEMON Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Byung Hwa HanEugene Investment & Securities Co Ltd.Jiyong LeeShinhan Investment Corp.Choongwoo SeoSK Securities Co., Ltd.
Reported Earnings • Nov 19Third quarter 2023 earnings released: ₩219 loss per share (vs ₩362 loss in 3Q 2022)Third quarter 2023 results: ₩219 loss per share (improved from ₩362 loss in 3Q 2022). Revenue: ₩6.47b (down 35% from 3Q 2022). Net loss: ₩4.68b (loss narrowed 19% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 26Second quarter 2023 earnings released: ₩115 loss per share (vs ₩237 profit in 2Q 2022)Second quarter 2023 results: ₩115 loss per share (down from ₩237 profit in 2Q 2022). Revenue: ₩9.85b (down 25% from 2Q 2022). Net loss: ₩2.45b (down 165% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
New Risk • Jun 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩140.8b (US$93.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (82% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩140.8b market cap, or US$93.4m).
New Risk • Apr 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩15b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩15b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 9.0% per year over the past 5 years. Shareholders have been substantially diluted in the past year (82% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩105.1b market cap, or US$69.7m).
お知らせ • Feb 24CORESTEMCHEMON Inc., Annual General Meeting, Mar 27, 2026CORESTEMCHEMON Inc., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 240, nampyeong-ro, yangji-eup, cheoin-gu, gyeonggi-do, yongin South Korea
分析記事 • Jan 23CORESTEMCHEMON Inc. (KOSDAQ:166480) Shares Fly 46% But Investors Aren't Buying For GrowthCORESTEMCHEMON Inc. ( KOSDAQ:166480 ) shareholders have had their patience rewarded with a 46% share price jump in the...
お知らせ • Dec 18Corestemchemon Advances Toward Als Stem Cell Commercialization with Regulatory Progress in Korea and Nsf-Backed U.S. ExpansionCorestemChemon is entering a critical late-stage phase in the commercialization of its ALS stem cell therapy, Neuronata-R. The company attributes this momentum to advanced domestic regulatory review in Korea, entry into an NSF-supported regenerative medicine ecosystem in the United States, secured commercialization capital, and a sizable open-market share purchase by the CEO. In Korea, Neuronata-R is undergoing a product license modification review by the Ministry of Food and Drug Safety (MFDS). Following mixed efficacy results in the overall patient population in the Phase 3 ALSUMMIT trial, CorestemChemon refined its regulatory strategy to focus on a clinically defined " slow progressor" subgroup. Post-hoc analyses in this subgroup showed clinically meaningful and internally consistent signals, including maintenance of ALS Functional Rating Scale-Revised (ALSFRS-R) scores, stabilization of slow vital capacity (SVC), and favorable trends in neurofilament light chain (NfL) biomarkers. The company believes these findings have supported a more structured and focused regulatory dialogue with the MFDS. The company expects this precision-targeted approach to further clarify the domestic regulatory pathway, while preserving the option for initial commercialization upon potential approval. A favorable MFDS decision would enable domestic market entry and generation of real-world evidence (RWE), which could support future global regulatory strategies. The company expects a final regulatory decision in Korea before the first quarter of 2026. CorestemChemon has been selected to join the Piedmont Triad Regenerative Medicine Innovation Engine, a U.S. regional innovation cluster supported by the National Science Foundation (NSF). The company stated that it is the first Korean biotechnology firm to be included in an NSF-backed regenerative medicine ecosystem. The selection was initiated by the Wake Forest Institute for Regenerative Medicine (WFIRM), which cited the scientific robustness of Neuronata-R's Phase 3 clinical dataset and the consistency observed in long-term real-world follow-up data. Participants in the NSF Engine is expected to provide access to translational research capabilities, manufacturing resources, and a broader regulatory network. To align more closely with this ecosystem, CorestemChemon plans to relocate its U.S. subsidiary to North Carolina. The company intends to leverage the cluster as a platform for regulatory engagement with the U.S. Food and Drug Administration (FDA), targeting submission of a Biologics License Application (BLA) in the third quarter of 2026. Commercialization Funding and Financial Position: To support commercialization readiness following potential domestic approval, CorestemChemon recently completed a rights offering, raising KRW 26.1 billion in operating capital (approximately USD 17.8 million, based on recent exchange rates). The proceeds are allocated to upgrading production facilities, establishing commercial-scale manufacturing systems, and preparing for both domestic and global regulatory processes. The company expects the capital raise to strengthen its financial position and reduce execution risk associated with manufacturing scale-up and regulatory preparation, while addressing near-term funding concerns. In a move widely interpreted as reinforcing market confidence, CEO Yang Gil-ahn recently executed a large-scale open-market share purchase. Over a two-week period, he acquired more than one million shares, representing an investment of approximately KRW 1.7 billion (approximately USD 1.2 million, based on recent exchange rate). The purchase coincided with the submission of supplementary regulatory materials to the MFDS and is viewed as a signal of management's conviction at a key regulatory inflection point. Following the transaction, the combined ownership stake of the controlling shareholder group increased to 10.32%, further strengthening alignment between management and shareholders.
分析記事 • Dec 03Investors Don't See Light At End Of CORESTEMCHEMON Inc.'s (KOSDAQ:166480) TunnelYou may think that with a price-to-sales (or "P/S") ratio of 3.4x CORESTEMCHEMON Inc. ( KOSDAQ:166480 ) is definitely a...
New Risk • Nov 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 82% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (82% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩48.3b market cap, or US$33.0m).
お知らせ • Nov 05CORESTEMCHEMON Inc. has completed a Follow-on Equity Offering in the amount of KRW 26.14 billion.CORESTEMCHEMON Inc. has completed a Follow-on Equity Offering in the amount of KRW 26.14 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: KRW 1307 Discount Per Security: KRW 23.526 Transaction Features: Rights Offering
お知らせ • Sep 18Neuronata- Phase 3 Results Confirm Subgroup Benefit at PACTALS 2025, Strengthening Biomarker-Driven PathwayCorestemChemon Inc. announced that it has presented key findings from the Phase 3 ALSummit trial of Neuronata-R® (lenzumestrocel), an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS), at the PACTALS 2025 congress in Melbourne, Australia. The first session, chaired by Professor Seung-Hyun Kim of Hanyang University Hospital — a global leader in stem cell-based ALS research — brought together a panel of seven distinguished ALS experts from six countries. As part of the panel, Dr. Ryung-A Lee (Head of R&D Innovation, CorestemChemon) introduced the company and shared a brief overview of the Phase 3 trial results. In the second session, the full Phase 3 clinical trial (ALSUMMIT trial) results were formally presented by Professor Ki-Uk Oh (Department of Neurology, Advanced Regenerative Medicine Center, Hanyang University Hospital, and principal investigator of the ALSUMMIT trial). Subgroup Analysis Demonstrates Statistically Significant Benefit: While the overall trial did not meet its primary and secondary endpoints, Neuronata-R® showed meaningful efficacy in patients with slower disease progression. At 12 months, participants in this subgroup receiving Neuronata-R achieved: ALSFRS-R (functional rating scale): 31.2 vs. 26.4 in placebo (p=0.001), CAFS (Combined Assessment of Function and Survival): 20.95 and 24.78 vs. 17.92 in placebo (p=0.024; p=0.041), SVC (slow vital capacity, respiratory function): 62.2% vs. 50.6% in placebo (p=0.017, Study Group 2). These findings confirm Neuronata-R's potential to preserve function and respiratory capacity in ALS — outcomes directly linked to quality of life and survival. Biomarker Data Underscore Neuroprotective Effect: Biomarker analysis revealed sustained reductions in neurofilament light chain (NfL) and MCP-1, indicating a strong link between neuroprotection and clinical outcomes. This strengthens the case for biomarker-guided patient stratification and a precision-medicine strategy in ALS drug development, reflecting the evolving global regulatory landscape. Regulatory Pathway Toward Accelerated Approval: CorestemChemon stated that the PACTALS 2025 results mark an important step for regulatory discussions. The company plans to request a Type-C meeting with the U.S. Food and Drug Administration (FDA) in Fourth Quarter 2025 to discuss the dataset and biomarker-driven subgroup efficacy. Based on this discussion, CorestemChemon plans to submit a Biologics License Application (BLA) within 2026, aiming to pursue an accelerated approval pathway aligned with precedents in ALS, including FDA's decision on Tofersen.
お知らせ • Aug 20CORESTEMCHEMON Inc. has filed a Follow-on Equity Offering in the amount of KRW 37.8 billion.CORESTEMCHEMON Inc. has filed a Follow-on Equity Offering in the amount of KRW 37.8 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: KRW 1890 Discount Per Security: KRW 34.02 Transaction Features: Rights Offering
分析記事 • Aug 19Why Investors Shouldn't Be Surprised By CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 40% Share Price PlungeThe CORESTEMCHEMON Inc. ( KOSDAQ:166480 ) share price has fared very poorly over the last month, falling by a...
New Risk • Aug 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩42b free cash flow). Earnings have declined by 18% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩50.3b market cap, or US$36.2m).
お知らせ • May 29Corestemchemon Announces Neuronata-R®? Stem Cell Therapy Shows Promise in Als Phase 3 Subgroup Analysis, Moves Toward Fda Accelerated ApprovalCorestemChemon announced Neuronata-R®?, an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS), has demonstrated meaningful efficacy signals in a subgroup of participants with slow disease progression in its recently completed Phase 3 trial. The therapy also showed consistent reductions in neurofilament light chain (NfL) levels -- a biomarker that served as the basis for FDA accelerated approval in ALS, including the recent decision on Tofersen -- supporting its potential to pursue a similar regulatory pathway. Developed by South Korean biotech company CorestemChemon, Neuronata-R®? utilizes MSCs derived from a participant's own bone marrow to modulate inflammation, protect motor neurons, and alter the neurodegenerative microenvironment through paracrine signaling. ALS, a rare and fatal disease with no cure, remains one of the most urgent areas of unmet medical need. Neuronata-R®®? aims to address the disease's complexology by leveraging the therapeutic potential of autologous MSCs. The final Clinical Study Report (CSR) confirmed that Neuronata-R®.
分析記事 • Apr 14CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Price Is Right But Growth Is LackingYou may think that with a price-to-sales (or "P/S") ratio of 3x CORESTEMCHEMON Inc. ( KOSDAQ:166480 ) is definitely a...
お知らせ • Feb 22CORESTEMCHEMON Inc., Annual General Meeting, Mar 28, 2025CORESTEMCHEMON Inc., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 240, nampyeong-ro, cheoin-gu, gyeonggi-do, yongin South Korea
分析記事 • Feb 20Is CORESTEMCHEMON (KOSDAQ:166480) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Dec 20New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩123.5b (US$85.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩41b free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩123.5b market cap, or US$85.3m).
New Risk • Dec 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩41b free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (14% increase in shares outstanding).
分析記事 • Dec 09CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Popularity With Investors Under Threat As Stock Sinks 25%CORESTEMCHEMON Inc. ( KOSDAQ:166480 ) shares have had a horrible month, losing 25% after a relatively good period...
分析記事 • Nov 01Is CORESTEMCHEMON (KOSDAQ:166480) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Sep 24CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 27% Price Boost Is Out Of Tune With RevenuesCORESTEMCHEMON Inc. ( KOSDAQ:166480 ) shares have had a really impressive month, gaining 27% after a shaky period...
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Shareholders have been diluted in the past year (2.6% increase in shares outstanding).
分析記事 • Aug 03Would CORESTEMCHEMON (KOSDAQ:166480) Be Better Off With Less Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Jun 08What CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 26% Share Price Gain Is Not Telling YouCORESTEMCHEMON Inc. ( KOSDAQ:166480 ) shares have continued their recent momentum with a 26% gain in the last month...
New Risk • May 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩26b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩26b free cash flow). Earnings have declined by 12% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).
New Risk • Apr 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.1% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change).
お知らせ • Mar 27CORESTEMCHEMON Inc. announced that it has received KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd.On March 26, 2024, CORESTEMCHEMON Inc., closed the transaction.
分析記事 • Mar 05CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Shares Bounce 25% But Its Business Still Trails The IndustryCORESTEMCHEMON Inc. ( KOSDAQ:166480 ) shares have continued their recent momentum with a 25% gain in the last month...
Reported Earnings • Nov 19Third quarter 2023 earnings released: ₩219 loss per share (vs ₩362 loss in 3Q 2022)Third quarter 2023 results: ₩219 loss per share (improved from ₩362 loss in 3Q 2022). Revenue: ₩6.47b (down 35% from 3Q 2022). Net loss: ₩4.68b (loss narrowed 19% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 26Second quarter 2023 earnings released: ₩115 loss per share (vs ₩237 profit in 2Q 2022)Second quarter 2023 results: ₩115 loss per share (down from ₩237 profit in 2Q 2022). Revenue: ₩9.85b (down 25% from 2Q 2022). Net loss: ₩2.45b (down 165% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
お知らせ • Jan 27CORESTEMCHEMON Inc. announced that it has received KRW 32.31145 billion in funding from a group of investorsOn January 26, 2023, CORESTEMCHEMON Inc. closed the transaction.
お知らせ • Jan 18CORESTEMCHEMON Inc. announced that it expects to receive KRW 21.5 billion in funding from a group of investorsCORESTEMCHEMON Inc. announced a private placement of series 2 unregistered coupon unguaranteed private convertible bonds for gross proceeds of KRW 21,500,000,000 on January 17, 2023. The transaction will include participation from Kiwoom Securities Co., Ltd., Investment Arm, JB Woori Capital Co., Ltd, returning investors, Hanyang Securities Co. Ltd., Asset Management Arm, Samsung Securities Co. Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm and KB Securities Co., Ltd., Investment Arm. The zero coupon bonds will have a yield to maturity rate of 1% maturing on January 19, 2027. The series 2 bonds will be fully convertible into 2,423,900 common shares at an issue conversion price of KRW 8,870 per share between the period starting from February 19, 2023 and ending on December 19, 2026. The bonds have a lock-up period of one year from the date of issuance. The expected date of payment is January 19, 2023. The transaction has been approved by board of directors of the company.
Valuation Update With 7 Day Price Move • Dec 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩8,380, the stock trades at a trailing P/E ratio of 34.9x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Negligible returns to shareholders over past three years.
Valuation Update With 7 Day Price Move • Oct 11Investor sentiment improved over the past weekAfter last week's 26% share price gain to ₩11,650, the stock trades at a trailing P/E ratio of 23.6x. Average trailing P/E is 20x in the Biotechs industry in South Korea. Total returns to shareholders of 25% over the past three years.
分析記事 • Apr 12Does CORESTEM (KOSDAQ:166480) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Feb 20New 90-day low: ₩19,150The company is down 8.0% from its price of ₩20,900 on 20 November 2020. The South Korean market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period.
分析記事 • Feb 16If You Had Bought CORESTEM (KOSDAQ:166480) Shares A Year Ago You'd Have Earned 59% ReturnsCORESTEM Inc. ( KOSDAQ:166480 ) shareholders have seen the share price descend 18% over the month. But looking back...
分析記事 • Dec 25Corestem (KOSDAQ:166480) Has Debt But No Earnings; Should You Worry?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Nov 16New 90-day low: ₩20,500The company is down 1.0% from its price of ₩20,650 on 18 August 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 3.0% over the same period.